daclizumab HYP: Clinical Trials

6 completed, 1 terminated. 3 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 3
Phase 3	3	Completed 2, Terminated 1
Phase 1	1	Completed 1

Follow daclizumab HYP: new trials by email Literature Review of daclizumab HYP trials Research Report on daclizumab HYP

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Daclizumab Japanese PK Study BIIB019 subcutaneous injection - Healthy	Phase 1	Completed	Biogen	56	2013-10-01	2014-05-02
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 BIIB019 (Daclizumab) - Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis	Phase 3	Terminated	Biogen	1501	2013-02-15	2019-12-04
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis Midazolam, Caffeine, S-warfarin - Relapsing-Remitting Multiple Sclerosis	Phase 3	Completed	Biogen	133	2011-11-01	2017-03-14
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a - Relapsing-Remitting Multiple Sclerosis	Phase 3	Completed	Biogen	1841	2010-05-01	2016-07-11
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis BIIB019 (Daclizumab), trivalent seasonal influenza vaccine - Relapsing-Remitting Multiple Sclerosis	Phase 2	Completed	Biogen	410	2010-03-31	2018-11-09
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis BIIB019 (Daclizumab High Yield Process), Placebo - Relapsing-Remitting Multiple Sclerosis	Phase 2	Completed	Biogen	517	2009-02-01	2016-08-30
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis BIIB019 (Daclizumab High Yield Process), Placebo - Relapsing-Remitting Multiple Sclerosis	Phase 2	Completed	Biogen	621	2008-02-01	2016-07-11

Conditions studied

Multiple Sclerosis, Relapsing-Remitting (6)  ·  Multiple Sclerosis (4)

Sponsors

Biogen (7)

Countries

Czechia (6)  ·  Hungary (6)  ·  Poland (6)  ·  United Kingdom (6)  ·  Germany (5)  ·  India (5)  ·  Russia (5)  ·  Ukraine (5)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)  ·  Canada (2)  ·  Denmark (2)  ·  France (2)

Results publications

PMID 27411694, PMID 23562009, PMID 24656609, PMID 25416807, PMID 26444729, PMID 27251051, PMID 27461166, PMID 28104250, PMID 28485186, PMID 28984179, PMID 32451615, PMID 37072219, PMID 37652990

NIH funding

2009 (2)